company background image
VBIV.Q logo

VBI Vaccines OTCPK:VBIV.Q Stock Report

Last Price

US$0.0005

Market Cap

US$14.3k

7D

0%

1Y

-99.9%

Updated

26 Dec, 2024

Data

Company Financials

VBIV.Q Stock Overview

A commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. More details

VBIV.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

VBI Vaccines Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for VBI Vaccines
Historical stock prices
Current Share PriceUS$0.0005
52 Week HighUS$1.35
52 Week LowUS$0.0002
Beta2.08
1 Month Change0%
3 Month Change-97.18%
1 Year Change-99.92%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

Sep 22

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

Sep 15

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

Sep 08

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09
Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Shareholder Returns

VBIV.QUS BiotechsUS Market
7D0%2.1%2.8%
1Y-99.9%-3.8%24.5%

Return vs Industry: VBIV.Q underperformed the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: VBIV.Q underperformed the US Market which returned 24.8% over the past year.

Price Volatility

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement61.3%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: VBIV.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VBIV.Q's weekly volatility has increased from 41% to 61% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a135Jeff Baxterwww.vbivaccines.com

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus.

VBI Vaccines Inc. Fundamentals Summary

How do VBI Vaccines's earnings and revenue compare to its market cap?
VBIV.Q fundamental statistics
Market capUS$14.34k
Earnings (TTM)-US$83.99m
Revenue (TTM)US$9.41m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VBIV.Q income statement (TTM)
RevenueUS$9.41m
Cost of RevenueUS$11.67m
Gross Profit-US$2.26m
Other ExpensesUS$81.73m
Earnings-US$83.99m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.93
Gross Margin-24.03%
Net Profit Margin-892.47%
Debt/Equity Ratio-891.6%

How did VBIV.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:57
End of Day Share Price 2024/12/24 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

VBI Vaccines Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guyn KimBMO Capital Markets Equity Research
Kumaraguru RajaBrookline Capital Markets
John NewmanCanaccord Genuity